A recent study presented at the European Association of Urology Congress shared the initial findings of the first long-term follow-up study on the safety and effectiveness of the Uromune™ (MV140) inactivate vaccine for recurrent Urinary Tract Infections (UTIs).
The results, announced on April 6, 2024, indicate that 54% of study participants, including men and women with recurrent UTIs, remained UTI-free for nine years after receiving the vaccine.
Read More
